Elanco Animal Health (ELAN) EBITDA Margin (2017 - 2026)

Elanco Animal Health has disclosed EBITDA Margin across 10 years of filings, most recently posting 18.13% for Q2 2026.

• In Q2 2026, EBITDA Margin rose 40.0% year-over-year to 18.13%; the TTM figure through Jun 2026 stood at 12.69% (up 1325.0% YoY), while the FY2025 annual figure was 11.83%, up 4596.0% from the prior year.
• EBITDA Margin came in at 18.13% for Q2 2026 at Elanco Animal Health, down from 21.23% in the prior quarter.
• In the past five years, EBITDA Margin ranged from a high of 21.23% in Q1 2026 to a low of 148.31% in Q3 2023.
• Average EBITDA Margin over 5 years is 28.91%, with a median of 38.57% recorded in 2024.
• Year-over-year, EBITDA Margin tumbled 9802 bps in 2023 and surged 15482 bps in 2024.
• Over 5 years, EBITDA Margin stood at 54.52% in 2022, then declined by 14 bps to 62.13% in 2023, then climbed by 13 bps to 54.12% in 2024, then soared by 93 bps to 3.85% in 2025, then jumped by 571 bps to 18.13% in 2026.
• Per Business Quant data, the three most recent EBITDA Margin figures were 18.13% in Q2 2026, 21.23% in Q1 2026, and 3.85% in Q4 2025.